Synthetic biology company Ginkgo Bioworks is toying with the idea of going public via a reverse merger with special-purpose acquisition company Soaring Eagle Acquisition Corp.

The potential deal, first reported by Bloomberg, could value Ginkgo at more than $20 billion — more than five times what Ginkgo was valued at in late 2019, when it last raised venture capital.

Ginkgo Bioworks declined to comment.

The news comes as deals with special-purpose acquisition companies, known as the number of…

Boston Biz Journal